A wealth of preclinical and clinical data has supported and accompanied the development of GLP‐1‐based therapies for type 2 diabetes and obesity (Gabery et al., 2020; Secher et al., 2014), a market now worth billions of dollars per year. This evidence concerns the gene GCG and type 2 diabetes mellitus.